Head-to-Head Comparison of Five Long-Acting GLP-1 Drugs Available in China | Research

The takeaway

A comprehensive clinical evaluation compared five long-acting GLP-1 receptor agonists available in China across multiple dimensions, providing evidence-based guidance for drug selection.

5 GLP-1 RAs compared
Multi-dimensional evaluation for Chinese medical institution formulary selection

What the researchers found

A structured multi-dimensional comparison of five long-acting GLP-1RAs in China provides evidence-based rankings for clinical preference and institutional formulary decisions.

Why it matters

With multiple GLP-1 options available, clinicians need objective comparisons to make the best prescribing decisions. This is especially important in China where healthcare resource allocation is centralized.

How the study worked

Structured drug evaluation following Chinese medical institution guidelines; multi-dimensional clinical assessment framework.

What this study cannot tell us

Evaluation framework is specific to Chinese healthcare context; may not include the newest GLP-1 drugs; subjective weighting of evaluation dimensions.

How to read the evidence

Structured drug evaluation following standardized guidelines — systematic but dependent on available evidence and evaluation criteria weighting.

When this study was published

Published in 2026, providing current formulary guidance as GLP-1 drug options expand in China.

The bigger picture

As GLP-1 drugs become available worldwide, each country needs localized evaluation frameworks that consider local drug availability, pricing, and healthcare system needs.

Questions still open

Do the top-ranked GLP-1 drugs in China differ from those preferred in Western healthcare systems?
How does cost-effectiveness weighting change the rankings compared to efficacy-only rankings?

Common questions

Which GLP-1 drug is best for type 2 diabetes?

It depends on individual patient needs, costs, and availability. This study evaluates five options across multiple factors including efficacy, safety, convenience, and cost to help match patients with the best drug.

Are the same GLP-1 drugs available everywhere?

No — different countries approve different GLP-1 drugs and generics/biosimilars. This study focuses specifically on the five long-acting options available in China, which may differ from options in the US or Europe.

Read the original research

A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.

Diabetes, metabolic syndrome and obesity : targets and therapy, 19, 585436

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Qiying; Chen, Tianyu; Lin, Weicheng; Chen, Xi. (2026). A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.. Diabetes, metabolic syndrome and obesity : targets and therapy, 19, 585436. https://doi.org/10.2147/DMSO.S585436